Specializes in the development and commercialization of therapies using its proprietary PharmFilm® technology to improve patient outcomes.
Aquestive Therapeutics, Inc. is a pharmaceutical innovator dedicated to identifying, developing, and commercializing a diverse range of products aimed at addressing critical unmet medical needs both in the United States and internationally. Founded in 2004 and headquartered in Warren, New Jersey, the company has established itself as a leader in advanced drug delivery technologies. Aquestive Therapeutics markets several key products including Sympazan, an oral soluble film formulation of clobazam for treating lennox-gastaut syndrome, and Suboxone, a sublingual film formulation of buprenorphine and naloxone used in the treatment of opioid dependence.
The company's portfolio also features Zuplenz, an oral soluble film formulation of ondansetron prescribed for managing nausea and vomiting associated with chemotherapy and post-operative recovery, and Azstarys, a once-daily treatment for attention deficit hyperactivity disorder. Aquestive's proprietary product candidates include Libervant, a buccal soluble film of diazepam for seizure treatment, and Exservan, an orral soluble film of riluzole designed for amyotrophic lateral sclerosis.
Continuing its commitment to innovation, Aquestive Therapeutics is advancing a robust pipeline of complex molecule products. This includes AQST-108, a sublingual film formulation delivering systemic epinephrine for conditions beyond anaphylaxis, AQST-305 for acromegaly treatment, and AQST-109, an orally delivered epinephrine product for emergency allergy treatment. Moreover, the company is developing KYNMOBI, a sublingual film of apomorphine to manage episodic off-periods in Parkinson's disease, underscoring its dedication to enhancing patient outcomes through cutting-edge pharmaceutical solutions.